Personalized vaccine offers hope for patients with late-stage kidney cancer, clinical trial shows
Researchers, in a sense, manipulated each patient’s cancer in an attempt to prevent it from coming back. Read More Source ...
Researchers, in a sense, manipulated each patient’s cancer in an attempt to prevent it from coming back. Read More Source ...
Lynparza (olaparib), a product of Fortune 500 pharmaceutical firm Merck and Fortune 500 Europe company AstraZeneca, showed meaningful improvements in ...
Merck will gain the exclusive global license for Chinese drugmaker Hansoh’s HS-10535, an experimental oral drug that targets GLP-1 receptors. ...